AUP:CA:TSX-Aurinia Pharmaceuticals Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 14.29

Change

0.00 (0.00)%

Market Cap

CAD 1.83B

Volume

0.10M

Avg Analyst Target

CAD 29.00 (+102.94%)

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada. Address: 4464 Markham Street, Victoria, BC, Canada, V8Z 7X8

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TRIL:CA Trillium Therapeutics Inc

N/A

CAD0.93B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

CAD0.54B 1.28 N/A
APS:CA Aptose Biosciences Inc

N/A

CAD0.31B N/A N/A
BLU:CA BELLUS Health Inc

N/A

CAD0.27B N/A N/A
FRX:CA Fennec Pharmaceuticals Inc

N/A

CAD0.21B 30.20 N/A
ATE:CA Antibe Therapeutics Inc

N/A

CAD0.18B N/A N/A
ONC:CA Oncolytics Biotech Inc

N/A

CAD0.17B N/A N/A
IMV:CA IMV Inc

N/A

CAD0.17B -99,999.99 N/A
RVX:CA Resverlogix Corp

N/A

CAD0.17B 50.00 26.37
MDNA:CA Medicenna Therapeutics Corp

N/A

CAD0.16B 5.40 N/A

ETFs Containing AUP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.62% 41% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.62% 41% F 8% F
Trailing 12 Months  
Capital Gain -23.54% 33% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.54% 33% F 7% F
Trailing 5 Years  
Capital Gain 255.47% 92% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 255.47% 92% A- 94% A
Average Annual (5 Year Horizon)  
Capital Gain 53.17% 72% C- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.17% 72% C- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 79.53% 50% F 10% F
Risk Adjusted Return 66.86% 94% A 77% C+
Market Capitalization 1.83B 100% A+ 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.97 41% F 23% F
Price / Cash Flow Ratio -26.22 79% C+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -40.13% 80% B- 11% F
Return on Invested Capital -28.59% 63% D 7% F
Return on Assets -21.82% 79% C+ 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.99 11% F 20% F
Short Percent 0.92% 18% F 60% D-
Beta 0.34 67% D+ 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector